ABSTRACT All-cause otitis media (OM) incidence has declined in numerous settings following introduction of pneumococcal conjugate vaccines (PCVs) despite increases in carriage of nonvaccine pneumococcal serotypes escaping immune pressure. To understand the basis for the declining incidence, we assessed the intrinsic capacity of pneumococcal serotypes to cause OM independently and in polymicrobial infections involving nontypeable Haemophilus influenzae (NTHi) using samples obtained from middle ear fluid and nasopharyngeal cultures before PCV7/13 rollout. Data included samples from OM episodes (11, 811) submitted for cultures during a 10-year prospective study in southern Israel and nasopharyngeal samples (1,588) from unvaccinated asymptomatic children in the same population. We compared data representing pneumococcal serotype diversity across carriage and disease isolates with and without NTHi coisolation. We also measured associations between the pneumococcal phenotype and the rate of progression from colonization to OM in the presence and absence of NTHi. Whereas pneumococcal serotype diversity was lower in single-species OM than in single-species colonization, levels of serotype diversity did not differ significantly between colonization and OM in mixed-species episodes. Serotypes differed roughly 100-fold in progression rates, and those differences were attenuated in polymicrobial episodes. Vaccine serotype pneumococci had higher rates of progression than nonvaccine serotypes. While serotype invasiveness was a weak predictor of the OM progression rate, efficient capsular metabolic properties-traditionally thought to serve as an advantage in colonization-predicted an enhanced rate of progression to complex OM. The lower capacity of nonvaccine serotypes to cause OM may partially account for reductions in all-cause OM incidence despite serotype replacement in carriage following rollout of PCVs.
factors influencing progression from colonization to OM are ideal targets for treating or preventing disease. Pneumococcal conjugate vaccines (PCVs) with capsular antigens from 7, 10, and 13 S. pneumoniae serotypes have recently been introduced to pediatric immunization schedules of most countries. The availability of only limited data from prelicensure studies has contributed to uncertainty about the basis of PCV-mediated protection against OM (2) (3) (4) , hampering efforts to interpret the considerable reductions reported in the levels of all-cause OM burden following PCV introduction in numerous settings (5) (6) (7) (8) amid cooccurring changes in the circulation of vaccine-targeted and nonvaccine serotypes (9) (10) (11) . Pneumococcal OM frequently involves the formation of polymicrobial biofilms with NTHi, and mixed-species infections represent a distinct clinical entity associated with recurrence, chronicity, and a unique serotype repertoire (12) . However, the contribution of bacterial factors to disease progression remains poorly understood. Insight into this aspect of OM pathogenesis can guide interpretations of vaccine impact and can inform serotype selection for extended-valency conjugate vaccines (13) as well as for next-generation vaccine development (14, 15) .
We analyzed isolates from MEF and asymptomatic nasopharyngeal colonization to better understand bacterial determinants of progression to complex OM. Using epidemiological surveillance data from southern Israel prior to PCV7/13 introduction, we compared the pneumococcal serotype distributions of single-species and mixedspecies carriage and OM and measured pathogen-specific rates of OM progression from asymptomatic colonization. We identified roughly 100-fold differences in the rates of pneumococcal serotype-specific progression to complex OM and found that these differences were attenuated in mixed-species episodes involving NTHi-further signaled by enhanced serotype diversity in polymicrobial OM relative to single-species episodes. Pneumococcal serotypes targeted by PCV13 are among the most virulent in terms of OM progression, a finding that may in part account for the reductions in all-cause OM incidence seen following PCV introduction despite serotype replacement in pneumococcal carriage.
RESULTS
Study enrollment. Data came from several studies undertaken prior to PCV7 introduction in southern Israel; we included samples obtained before July 2008 in the analyses (Table 1) . Nasopharyngeal carriage of S. pneumoniae and NTHi was monitored among PCV7/13-unvaccinated children who were 2 to 18 months of age and were enrolled in a randomized trial of PCV7 dosing strategies between 2005 and 2008 (17, 22) . The samples submitted from children totalled 1,588; among those, S. pneumoniae was detected in 743 (46.8%) swabs, NTHi was detected in 524 (33.0%) swabs, and the two species were coisolated in 376 (23.7%). A 10-year prospective study of the incidence of severe OM cases necessitating MEF culture (as indicated by complex manifestations [detailed in Materials and Methods]) supplied samples totalling 11,811 cases (12), with 4,165 (35.3%) positive for S. pneumoniae, 4,813 (40.8%) positive for NTHi, and 1,589 (13.5%) positive for the two species. Other previously conducted laboratory and epidemiological studies supplied phenotype information about pneumococcal serotypes (18) (19) (20) (21) . Further descriptive details, including age-specific OM incidence and carriage prevalence as well as serotype frequencies in carriage and disease, are provided as supporting information (see Fig. S1 and Table S1 in the supplemental material).
Pneumococcal serotype distribution in single-species and mixed-species colonization and otitis media. If serotype factors play a role in progression of pneumococcal colonization to OM, the diversity of serotypes isolated from MEF would be expected to differ from the diversity of serotypes carried in the nasopharynx (23) . To investigate this hypothesis, we calculated Simpson's diversity index (D) values for pneumococcal serotypes isolated from MEF and from carriage, with and without cooccurring NTHi, and tested for differences in serotype diversity (Fig. 1) ; D measures the probability that any two randomly chosen isolates would belong to different serotypes (see Materials and Methods).
Pneumococcal serotype diversity was higher in nasopharyngeal isolates than in MEF isolates both in the presence and in the absence of NTHi (P Ͻ 10 -4 ), consistent with the hypothesis that a limited number of serotypes cause a disproportionate disease burden. However, in mixed infections, the difference was no longer significant (P ϭ 0.11). Whereas serotype diversity was lower in the presence of NTHi during colonization, an opposite relationship was seen in MEF isolates, where diversity was significantly lower in single-species than in mixed-species infections (P ϭ 0.022).
We next sought to determine whether the similar results seen with respect to pneumococcal serotype diversity in mixed-species colonization and OM were a conse- (Fig. 2) . We identified lower divergence between serotype distributions of mixed-species carriage and OM than between serotype distributions of single-species carriage and mixedspecies OM (P Ͻ 0.01)-a finding that supports the idea of serotype-specific polymicrobial interactions in carriage as the basis for patterns of cooccurrence in disease. The divergence between the pneumococcal serotype distributions of mixed-species OM and single-species OM was lower, however, suggesting an overriding role of the pneumococcal serotype in both single-species and mixed-species OM progression. Determinants of progression from colonization to OM. We next compared pathogen-specific rates of progression to OM episodes necessitating MEF in order to identify bacterial factors associated with virulence. We derived the odds ratio of disease as an expression of the relative rate of progression from asymptomatic colonization to OM (see Materials and Methods).
Progression rates for pneumococcal serotypes spanned over 2 orders of magnitude (Fig. 3) . The highest progression rates were detected among PCV13 serotypes, including 1, 3, 5, and 7F; for the latter two serotypes, which were detected in 24 and 101 single-species OM cases, respectively, no instances of single-species carriage were detected. Although we also detected no single-species carriage of 7B and 24F, these serotypes accounted for only 6 and 4 single-species OM episodes, respectively. Though not detected in mixed-species colonization, serotypes 8, 33F, and 15B/C were isolated from samples representing 4, 28, and 48 instances of mixed-species OM, respectively. Unencapsulated pneumococci had the lowest measured progression rates for singlespecies OM, while no instances of single-species OM involved serotype 22F or serotype 19B. We did not identify strong statistical evidence (defined by a 95% confidence interval [CI] entirely above 1) that any serotype had a higher progression rate than NTHi.
Serotype differences in progression for mixed-species episodes were attenuated in comparison to differences in progression for single-species episodes. We identified lower progression rates in mixed-species episodes involving serotypes that tended otherwise to be virulent when they colonized in the absence of NTHi, including 6A, 6B, 14, 18C, 17F, 19A, 19F, and 31. Only nontypeable pneumococci and serotypes 20 and 31 showed increased progression rates in association with NTHi. To understand this variation with respect to progression to OM, we used regression models to calculate associations between phenotypes and progression rates for singlespecies and mixed-species episodes. To enable comparisons of effect sizes, we scaled all phenotype variables to unit variance (Table 2; see also Table S2 ). We estimated a 50% (95% CI, 31% to 72%) increase in progression rate for each increase by 1 standard deviation in the metabolic efficiency of capsule production-a strong predictor of pneumococcal fitness in colonization (18) and of the capacity to cocolonize with NTHi (23)-which was not apparent in polymicrobial episodes. We identified a weak, 14% (95% CI, 1% to 29%) increase in the progression rate for each increase in serotype invasiveness by 1 standard deviation, reflecting our findings that invasive-diseaseassociated serotypes (e.g., 1, 4, 5, and 14) were among those more likely to cause OM together with serotypes such as 3 and 15B/C, which are less invasive. We identified similar associations between higher progression rates and thinner encapsulations and lower case-fatality ratios, which are associated with invasiveness (24) , and with a weaker surface charge in mixed-species episodes.
Our analyses also revealed a 77.5% (95% CI, 46.3% to 114.5%)-higher progression rate during the months with the highest degree of respiratory virus transmission (December to March), compounding the effect of elevated carriage prevalence during these months as a driver of seasonal OM incidence (17) .
DISCUSSION
We sought to better understand the progression of S. pneumoniae and NTHi to complex OM manifestations using prospectively gathered epidemiological surveillance data from Israel. We identified over-100-fold differences in the rates at which pneumococcal serotypes progress from colonization to OM. Serotypes 1, 3, 5, 7B, 7F, and 24F showed the greatest virulence as causes of single-species infections; in addition, serotypes 8, 15B/C, and 33F showed particularly high rates of mixed-species progression with NTHi. A narrower range of mixed-species progression rates, together with elevated serotype diversity in mixed-species disease relative to single-species disease, suggested that interactions with NTHi may attenuate serotype-specific differences in disease potential. While we identified a weak positive association between OM progression rates and the risk that serotypes would cause invasive pneumococcal disease (IPD), we also found that each standard-deviation increase in the metabolic efficiency of a serotype-typically a marker for colonization fitness and lower virulence (18)-was associated with a 50% increase in the rate of OM progression. Taken together, our findings substantiate the role of bacterial factors, including serotype-specific interactions with NTHi, in the pathogenesis of complex pneumococcal OM.
Our findings aid interpretation of the impact of PCV on OM. Shortly after vaccine introduction, concerns arose regarding the possibility that the replacement of PCVtargeted serotypes by nonvaccine serotypes in carriage might offset the impact of vaccine on OM (25), consistent with observations in IPD (26) . Nonetheless, studies in Israel (16) and other settings (5) have reported declines in the incidence of all-cause OM following PCV rollout. Although comparable epidemiological surveillance was not undertaken in the United States, reductions in all-cause OM incidence relative to the prevaccine era (27) are apparent from the proportion of children experiencing primary and subsequent OM episodes during each year of life (28, 29) and from reduced health care utilization for cases of severe OM (8, (30) (31) (32) . While the effects of serotype replacement in carriage are apparent from the changing serotype distribution of OM episodes in Israeli studies as well as in U.S. studies (16, 28, 33) , our finding of lower virulence among nonvaccine replacement serotypes helps to account for overall reductions in OM incidence following vaccine introduction. Because the tissue damage sustained during early-life OM episodes historically associated with PCV13 serotypes contributes to the risk of secondary infections (34), PCV7/13-mediated protection against OM caused by these virulent lineages may also contribute indirectly to the reduced incidence of OM caused by other pathogens, including NTHi and nonvaccine pneumococcal serotypes (16, 35) . a Pneumococcal attributes are defined in Table 1 . b Progression rates were compared via the odds ratio, as calculated by logistic regression with an exchangeable correlation structure to account for repeated carriage observations from individual children. Due to collinearity among serotype measurements, individual models are fitted for each association. Our derivation of the odds ratio as the relative progression rate is described in Materials and Methods. Boldface type indicates two-sided P Ͻ 0.05 in a model fitted with generalized estimating equations to account for repeated sampling of children. c Models were controlled for Jewish/Bedouin ethnicity and respiratory virus season (December to March).
Previous studies demonstrating differences in pneumococcal-serotype-specific disease potential have provided important evidence of the role of the capsule as a virulence factor in OM (25, 36) and in other pneumococcal disease manifestations (21, 37) . Smaller sample sizes, however, limited the statistical power of such studies and thus their ability to detect differences in serotype-specific rates of progression, contributing to concerns that serotype replacement may offset vaccine-attributable reductions in OM burden (25) . Data from over 13,000 isolates gathered through prospective, population-based surveillance enabled us to compare progression rates of 41 serotypes, stratifying according to coisolation with NTHi and thus identifying greater differences in disease potential than were previously recognized.
The biological basis for variation among serotypes in the capacity to cause OM is incompletely understood and likely multifactorial. Epidemiological observations suggest that OM is frequently a consequence of prior viral infection in the upper respiratory tract (29, 38, 39) , a finding supported by in vivo studies demonstrating that altered expression of bacterial adherence receptors and inflammation after viral infection facilitate bacterial infiltration of the middle ear (40) . A growing body of evidence suggests such that bacterial-viral interactions correlating with disease progression may be serotype specific. In experimentally challenged ferrets, influenza A infection enhanced the recovery of S. pneumoniae in nasal wash samples in a serotype-dependent manner and disproportionately enhanced the capacity of serotype 7F to cause OM (41); this serotype likewise showed considerable disease potential in our study. In mice, influenza A virus infection modified proinflammatory cytokine responses to S. pneumoniae differentially among serotypes and was a prerequisite to pathogenesis following nonlethal challenge with serotypes 19F and 7F (42) . Although the immunological pathway was not determined, a separate study showed that live attenuated influenza vaccination triggered increases in the duration and density of upper respiratory carriage of these serotypes, which may contribute to enhanced risk of upper respiratory mucosal disease (43) . Respiratory syncytial virus (RSV) is the most prevalent virus in MEF (44) and may contribute to OM pathogenesis through dysregulation of local antipneumococcal immune responses in a similar manner (40) . Additionally, in vitro studies have demonstrated serotype-dependent enhancement of pneumococcal adherence to RSVinfected epithelial cells (45) .
While interactions with NTHi, including biofilm formation, may alter species-specific viral-bacterial interactions (46) , our analysis suggests that the rank order of serotype virulence is nonetheless relatively consistent in the presence and absence of NTHi. Given evidence from our study of the significance of the capsule as a virulence determinant, the attenuation that we have observed in serotype-specific virulence differences in association with NTHi, and the enhanced serotype diversity in mixedspecies OM, may relate to downregulation of capsule expression in mixed-species biofilms (47) . Our finding that many serotypes show lower rates of progression to OM under conditions of cocolonization with NTHi reflects "stable" characteristics of mixedspecies infection in a chinchilla model (48) . However, this observation in our study may also reflect acquisition of NTHi at older, less-susceptible ages (see Fig. S1 in the supplemental material) or reduced sensitivity for the detection of bacteria in polymicrobial biofilms (34, 49) .
Our analysis has certain limitations. An ideal prospective study of OM progression would monitor nasopharyngeal carriage and OM incidence with MEF culture within a cohort of children to assess pathogen-specific OM incidence rates during colonization. The sample size needed to characterize serotype differences in progression in such a study would be prohibitively large, however; thus, microbiologically detailed prospective studies of carriage and disease provide a good alternative for characterizing pathogen-specific virulence (25, 35, 36, 50) . The validity of evaluation of progression via OM incidence per carrier is suggested by meta-analytic findings of high (Ͼ80%) concordance in S. pneumoniae and NTHi detection from nasopharyngeal and MEF cultures in severe OM cases (51), such as those necessitating MEF culture in our study. Nonetheless, molecular diagnostic tools may offer enhanced sensitivity in comparison to culture as performed here (52) (53) (54) . Such methods may be particularly important for estimating progression rates of serotypes that are rarely detected in carriage or disease: despite the large sample population used in our study, odds ratio estimates were sensitive to the lack of detection of episodes of either carriage (e.g., serotypes 5, 7B, 7F, 8, 15B/C, 24F, and 33F) or disease (serotypes 19B and 22F) in both single-species and mixed-species contexts. Although our analysis did not characterize the contribution of viral infections to disease onset and progression (38, 55) , their impact is suggested in our analysis by elevated progression rates during the winter months.
Note that our sample was enriched with complex OM cases due to the indications for obtaining MEF culture in the original prospective study. Thus, comparisons in our analysis reflect differences in progression to severe OM and may not represent the broader spectrum of illness, including acute OM episodes. Children who experience complex OM may differ from those experiencing acute OM; a higher prevalence of pneumococcal, NTHi, and polymicrobial colonization has been reported among otitisprone children compared to non-otitis-prone children owing to deficient mucosal antibody responses (56, 57) . High rates of NTHi progression in the absence of S. pneumoniae may also reflect a predominance of this pathogen in secondary infections following tissue damage associated with early-life OM (34) . Nonetheless, the use of NTHi as a reference category does not impact our ability to compare relative progression rates among serotypes.
Using data obtained prior to the establishment of widespread immunity to certain pneumococcal serotypes through routine PCV7/13 immunization, our report demonstrates greater variation in the capacity of pneumococcal serotypes to cause OM than has been previously recognized, as well as serotype-dependent alteration of disease potential associated with interaction with NTHi. High OM progression rates for PCVtargeted serotypes help to account for observations of reduced all-cause OM incidence following vaccine rollout despite serotype replacement in carriage. Epidemiological evidence from our study should inform mechanistic studies addressing the biological basis for variations in the capacity of serotypes to progress to OM in single-species and polymicrobial episodes. In addition, our estimates of serotype-specific virulence can inform development of future anticapsular and next-generation vaccines.
MATERIALS AND METHODS
Setting. Previously published studies provided data on the incidence of severe OM necessitating MEF culture (16) and the prevalence of bacterial carriage (17, 22) among Bedouin and Jewish children in the Negev region of southern Israel. The Bedouin population is transitioning from nomadic lifestyles to permanent settlements and has larger family sizes, higher levels of overcrowding, and lower socioeconomic status than the nearby Jewish population (58) . Bedouin children tend to experience higher rates of bacterial carriage and disease than Jewish children, despite receiving care from the same facilities (17) .
Data sets. (i) OM incidence and carriage prevalence. The incidence of OM episodes necessitating MEF culture is monitored routinely at the Soroka University Medical Center (SUMC) through an ongoing prospective, population-based epidemiological surveillance program. Over 95% of children in the Negev region receive care at SUMC. Indications for MEF culture are based on clinical severity and include, but are not limited to, previous OM or tube insertion at any time, high-grade fever or toxic appearance, and spontaneous drainage, as detailed previously (16); these criteria did not change during the study period.
The prevalence of nasopharyngeal S. pneumoniae and NTHi carriage was monitored in a preimplementation trial of PCV7 dosing schedules, where receipt of a first vaccine dose was randomized to the period between 2 and 18 months of age (22) ; data regarding pneumococcal and NTHi cocolonization have been published previously (17, 23) . We included data from all visits by unvaccinated children at up to the age of 18 months.
(ii) Bacteriological procedures. Samples of MEF were obtained by tympanocentesis or spontaneous drainage and placed in MW173 Amies transport medium (Transwab; Medical Wire and Equipment, Potley, United Kingdom) before being plated, within 16 h, on Trypticase agar (5% sheep blood and 5 g/ml gentamicin) and chocolate agar media, followed by 48 h of incubation at 35°C in 5% CO 2 . Laboratory procedures for identification of S. pneumoniae and NTHi were consistent in the studies of carriage and MEF and have been described previously (22) . Pneumococcal serotypes were determined by the Quellung reaction (antisera from Statens Serum Institut, Copenhagen, Denmark). Studies received ethics approval from SUMC, and the institutional review board at Harvard T.H. Chan School of Public Health exempted the secondary analyses from the need for approval.
(iii) Pneumococcal serotype measurements. We used previously obtained measurements of pneumococcal phenotypes in our analyses of factors associated with progression rate. These included the negative surface charge of the capsule (a determinant of susceptibility to phagocytosis) (19) ; the metabolic efficiency of capsule production, measured by the inverse of the number of carbons per repeat unit of the polysaccharide (18) ; the ability of serotypes to survive neutrophil-mediated killing in an in vitro surface assay (18) ; the width of the capsule (18) ; the likelihood for serotypes to cause death during invasive pneumococcal disease (IPD) (20) ; and the likelihood for serotypes to progress from carriage to IPD (21) .
Statistical analysis. (i) Serotype distribution in carriage and otitis media. We measured serotype diversity (D) as follows:
where p i values indicate the proportions of isolates belonging to serotype i. We used bootstrap resampling to measure confidence intervals around estimates and to test for differences in diversity in carriage and OM, applying data corresponding to a cluster bootstrap of children to account for repeated sampling in the carriage studies (23) .
We used Kullback-Leibler divergence to measure the similarity of the pneumococcal serotype distribution in mixed-species OM to the serotype distributions of the following clinical entities: pneumococcal OM without NTHi, pneumococcal carriage without NTHi, and mixed-species carriage of S. pneumoniae and NTHi. We sampled from Dirichlet-multinomial posterior distributions of serotype frequencies, applying a flat (Jeffreys) measure prior to account for uncertainty in sparse observations (59) . Measures closer to zero indicate greater similarity to the pneumococcal serotype distribution of mixedspecies OM. Consistent with our analyses of Simpson diversity, we generated credible intervals and conducted hypothesis testing via the bootstrap method for disease isolates and via the cluster bootstrap method for carriage isolates.
(ii) Variations in otitis media progression rates. Odds ratios calculated from counts (Y) of pathogen-specific carriage and disease episodes supplied the relative rates of progression from colonization to OM, measured as (cases/year)/carrier. Defining the prevalence of colonization by agent i and agent j as i and j and the rates of OM incidence as i and j , the theoretical basis of this interpretation is as follows: On the basis of the same premise, we used the odds ratio of OM to quantify the association between pneumococcal serotype factors and the rate of progression from colonization to OM in the presence and absence of NTHi. Defining e ␣ 0 and e ␤0 as the "baseline" rates of OM incidence and prevalence of colonization, respectively, and e ␣ 1 X and e ␤ 1 X as representative of the multiplicative impacts of a serotype factor X on incidence and prevalence, respectively, gives the following equation: which again represents the relative progression rate as the fold increase in incidence for X ϭ 1 (in comparison to the reference [ref.
] value of X ϭ 0), normalized by any effect of X on carriage prevalence. We used logistic regression to calculate odds ratios and adjusted odds ratios, controlling for the seasonal peak in virus transmission (months December to March) and Jewish or Bedouin ethnicity. Because differing numbers of children were retained in the unvaccinated group of the carriage study across ages, it was not possible to adjust for age in the odds ratio formulation described above; however, the narrow age range considered (Յ18 months) limited bias. We fitted models via generalized estimating equations with an exchangeable correlation structure to account for repeated sampling of children in the carriage studies.
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